Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + ipatasertib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + ipatasertib + nab-paclitaxel is a combination regimen under investigation for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). Atezolizumab is a monoclonal antibody immune checkpoint inhibitor targeting PD-L1, enhancing anti-tumor immune responses. Ipatasertib is an oral small molecule inhibitor of AKT, a key kinase in the PI3K/AKT pathway involved in tumor cell survival and proliferation. Nab-paclitaxel is an albumin-bound formulation of paclitaxel, a microtubule-stabilizing chemotherapeutic agent that inhibits cell division. The triplet aims to combine immunotherapy with targeted therapy and cytotoxic chemotherapy to improve outcomes in TNBC patients[1][2][5][6].
- Other names
- atezo + ipat + nab-pacatezolizumab plus ipatasertib plus nab-paclitaxel
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + ipatasertib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + ipatasertib + nab-paclitaxel.